{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Drug design", "Medicinal plants", "SARS-CoV-2"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34484639", "DateRevised": {"Year": "2022", "Month": "04", "Day": "26"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.18502/ajmb.v13i3.6370"], "Journal": {"ISSN": "2008-2835", "JournalIssue": {"Volume": "13", "Issue": "3", "PubDate": {"Year": "2021", "Season": "Jul-Sep"}}, "Title": "Avicenna journal of medical biotechnology", "ISOAbbreviation": "Avicenna J Med Biotechnol"}, "ArticleTitle": "The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds.", "Pagination": {"StartPage": "107", "EndPage": "115", "MedlinePgn": "107-115"}, "Abstract": {"AbstractText": ["The cause of COVID-19 global pandemic is SARS-CoV-2. Given the outbreak of this disease, it is so important to find a treatment. One strategy to cope with COVID-19 is to use the active ingredients of medicinal plants. In this study, the effect of active substances was surveyed in inhibiting four important druggable targets, including S protein, 3CLpro, RdRp, and N protein. RdRp controls the replication of SARS-CoV-2 and is crucial for its life cycle. 3CLpro is the main protease of the virus and could be another therapeutic target. Moreover, N protein and S protein are responsible for SARS-CoV-2 assembly and attaching, respectively.", "The 3D structures of herbal active ingredients were prepared and docked with the mentioned SARS-CoV-2 proteins to obtain their affinity. Then, available antiviral drugs introduced in other investigations were docked using similar tools and compared with the results of this study. Finally, other properties of natural compounds were uncovered for drug designing.", "The outcomes of the study revealed that Linarin, Amentoflavone, (-)-Catechin Gallate and Hypericin from <i>Chrysanthemum morifolium</i>, <i>Hypericum perforatum</i>, <i>Humulus lupulus</i>, and <i>Hibiscus sabdariffa</i> had the highest affinity for these basic proteins and in some cases, their affinity was much higher than antiviral medicines.", "In addition to having high affinity, these herb active ingredients have antioxidant, vasoprotective, anticarcinogenic, and antiviral properties. Therefore, they can be used as extremely safe therapeutic compounds in drug design studies to control COVID-19."], "CopyrightInformation": "Copyright\u00a9 2021 Avicenna Research Institute."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Microbial Biotechnology, Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran."}], "LastName": "Mahmoudi", "ForeName": "Samira", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Cell and Molecular Biology, Faculty of Biology, Nour Danesh Institution of Higher Education, Meymeh, Iran."}], "LastName": "Balmeh", "ForeName": "Negar", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Sciences and Agricultural Engineering, School of Agricultural Sciences, Pir Bakran Branch, Payame Noor University, Isfahan, Iran."}], "LastName": "Mohammadi", "ForeName": "Niloofar", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biotechnology, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran."}], "LastName": "Sadeghian-Rizi", "ForeName": "Tahereh", "Initials": "T"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Iran", "MedlineTA": "Avicenna J Med Biotechnol", "NlmUniqueID": "101511065", "ISSNLinking": "2008-2835"}, "CoiStatement": "Conflict of Interest Authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579 (7798):270\u20133.", "ArticleIdList": ["PMC7095418", "32015507"]}, {"Citation": "Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature 2020;579(7798):265\u20139.", "ArticleIdList": ["PMC7094943", "32015508"]}, {"Citation": "Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. Gorbalenya AA, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 2020:536\u201344.", "ArticleIdList": ["PMC7095448", "32123347"]}, {"Citation": "Malik YA. Properties of Coronavirus and SARS-CoV-2. Malays J Pathol 2020;42(1):3\u201311.", "ArticleIdList": ["32342926"]}, {"Citation": "Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814\u201320.", "ArticleIdList": ["23075143"]}, {"Citation": "De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol 2016;14(8):523\u201334.", "ArticleIdList": ["PMC7097822", "27344959"]}, {"Citation": "Liu X, Liu C, Liu G, Luo W, Xia N. COVID-19: Progress in diagnostics, therapy and vaccination. Theranostics 2020;10(17):7821\u201335.", "ArticleIdList": ["PMC7359073", "32685022"]}, {"Citation": "Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Publishing Group; 2020.", "ArticleIdList": ["32127666"]}, {"Citation": "Lisi L, Lacal PM, Barbaccia ML, Graziani G. Approaching Coronavirus Disease 2019: mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. Biochem Pharmacol 2020;114169.", "ArticleIdList": ["PMC7375972", "32710969"]}, {"Citation": "Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181(2):281\u201392.", "ArticleIdList": ["PMC7102599", "32155444"]}, {"Citation": "Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of SARS-CoV\u2014a target for vaccine and therapeutic development. Nat Rev Microbiol 2009;7(3): 226\u201336.", "ArticleIdList": ["PMC2750777", "19198616"]}, {"Citation": "Du L, Yang Y, Zhou Y, Lu L, Li F, Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 2017;21(2):131\u201343.", "ArticleIdList": ["PMC5457961", "27936982"]}, {"Citation": "Datta PK, Liu F, Fischer T, Rappaport J, Qin X. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 2020;10(16):7448\u201364.", "ArticleIdList": ["PMC7330865", "32642005"]}, {"Citation": "Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181(2): 271\u201380.", "ArticleIdList": ["PMC7102627", "32142651"]}, {"Citation": "Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 2020;11(1):1620.", "ArticleIdList": ["PMC7100515", "32221306"]}, {"Citation": "Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92(4):418\u201323.", "ArticleIdList": ["PMC7167049", "31967327"]}, {"Citation": "Fung TS, Liu DX. Coronavirus infection, ER stress, apoptosis and innate immunity. Front Microbiol 2014;5: 296.", "ArticleIdList": ["PMC4060729", "24987391"]}, {"Citation": "Peng H, Yang L, Wang L, Li J, Huang J, Lu Z, et al. Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-re-covered patients. Virology 2006;351(2):466\u201375.", "ArticleIdList": ["PMC7111820", "16690096"]}, {"Citation": "Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 2020;12(3):254.", "ArticleIdList": ["PMC7150947", "32106567"]}, {"Citation": "Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgen-feld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003;300 (5626):1763\u20137.", "ArticleIdList": ["12746549"]}, {"Citation": "Needle D, Lountos GT, Waugh DS. Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity. Acta Crystallogr Sect D Biol Crystallogr 2015;71(5):1102\u201311.", "ArticleIdList": ["PMC4427198", "25945576"]}, {"Citation": "ul Qamar MT, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal 2020;10(4):313\u20139.", "ArticleIdList": ["PMC7156227", "32296570"]}, {"Citation": "Smertina E, Urakova N, Strive T, Frese M. Calicivirus RNA-dependent RNA polymerases: evolution, structure, protein dynamics and function. Front Microbiol 2019; 10:1280.", "ArticleIdList": ["PMC6563846", "31244803"]}, {"Citation": "Liu W, Morse JS, Lalonde T, Xu S. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019- nCoV. Chembiochem 2020; 21(5):730\u20138.", "ArticleIdList": ["PMC7162020", "32022370"]}, {"Citation": "Lung J, Lin Y, Yang Y, Chou Y, Shu L, Cheng Y, et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol 2020;92 (6):693\u20137.", "ArticleIdList": ["PMC7228302", "32167173"]}, {"Citation": "Jia H, Gong P. A structure-function diversity survey of the RNA-dependent RNA polymerases from the positive-strand RNA viruses. Front Microbiol 2019;10:1945.", "ArticleIdList": ["PMC6713929", "31507560"]}, {"Citation": "Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. Cells 2020;9(5):1267.", "ArticleIdList": ["PMC7291026", "32443810"]}, {"Citation": "Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res 2020;104762.", "ArticleIdList": ["PMC7132364", "32147496"]}, {"Citation": "Chandel V, Sharma PP, Raj S, Choudhari R, Rathi B, Kumar D. Structure-based drug repurposing for targeting Nsp9 replicase and spike proteins of severe acute respiratory syndrome coronavirus 2. J Biomol Struct Dyn 2020;1\u201314.", "ArticleIdList": ["PMC7484568", "32838660"]}, {"Citation": "Alexpandi R, De Mesquita JF, Pandian SK, Ravi AV. Quinolines-based SARS-CoV-2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: an in silico analysis. Front Microbiol 2020;11:1796.", "ArticleIdList": ["PMC7390959", "32793181"]}, {"Citation": "Mosquera-Yuqui F, Lopez-Guerra N, Moncayo-Palacio EA. Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations. J Biomol Struct Dyn 2020;1\u201314.", "ArticleIdList": ["PMC7657401", "33084512"]}, {"Citation": "Lalani S, Poh CL. Flavonoids as antiviral agents for Enterovirus A71 (EV-A71). Viruses 2020;12(2):184.", "ArticleIdList": ["PMC7412425", "32630136"]}, {"Citation": "Jo S, Kim S, Shin DH, Kim MS. Inhibition of SARS-CoV 3CL protease by flavonoids. J Enzyme Inhib Med Chem 2020;35(1):145\u201351.", "ArticleIdList": ["PMC6882434", "31724441"]}, {"Citation": "Hulo C, De Castro E, Masson P, Bougueleret L, Bairoch A, Xenarios I, et al. ViralZone: a knowledge resource to understand virus diversity. Nucleic Acids Res 2011;39 (Database issue):D576\u201382.", "ArticleIdList": ["PMC3013774", "20947564"]}, {"Citation": "Pruitt KD, Tatusova T, Maglott DR. NCBI Reference Sequence (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins. Nucleic Acids Res 2005;33(Database issue):D501\u20134.", "ArticleIdList": ["PMC539979", "15608248"]}, {"Citation": "Haasnoot J, Berkhout B. RNAi and cellular miRNAs in infections by mammalian viruses. In: Antiviral RNAi. Springer; 2011. p. 23\u201341.", "ArticleIdList": ["PMC7120436", "21431677"]}, {"Citation": "Peele KA, Chandrasai P, Srihansa T, Krupanidhi S, Sai AV, Babu DJ, et al. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study. Inform Med Unlocked 2020; 100345.", "ArticleIdList": ["PMC7211761", "32395606"]}, {"Citation": "Matsuyama S, Nagata N, Shirato K, Kawase M, Takeda M, Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J Virol 2010;84(24): 12658\u201364.", "ArticleIdList": ["PMC3004351", "20926566"]}, {"Citation": "Shulla A, Heald-Sargent T, Subramanya G, Zhao J, Perlman S, Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry. J Virol 2011; 85(2):873\u201382.", "ArticleIdList": ["PMC3020023", "21068237"]}, {"Citation": "Filimonov DA, Lagunin AA, Gloriozova TA, Rudik AV, Druzhilovskii DS, Pogodin PV, et al. Prediction of the biological activity spectra of organic compounds using the PASS online web resource. Chem Heterocycl Compd 2014;50(3):444\u201357."}, {"Citation": "Maunz A, G\u00fctlein M, Rautenberg M, Vorgrimmler D, Gebele D, Helma C. Lazar: a modular predictive toxicology framework. Front Pharmacol 2013;4:38.", "ArticleIdList": ["PMC3669891", "23761761"]}, {"Citation": "Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis 2020;20(7):816\u201326.", "ArticleIdList": ["PMC7172901", "32325038"]}, {"Citation": "Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396 (10249):479\u201388.", "ArticleIdList": ["PMC7836858", "32702299"]}, {"Citation": "Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci 2020;16(10):1678\u201385.", "ArticleIdList": ["PMC7098030", "32226285"]}, {"Citation": "Zheng L, Zhang L, Huang J, Nandakumar KS, Liu S, Cheng K. Potential treatment methods targeting 2019-nCoV infection. Eur J Med Chem 2020;112687.", "ArticleIdList": ["PMC7385720", "32771797"]}, {"Citation": "Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res 2020;157:104833.", "ArticleIdList": ["PMC7194807", "32302706"]}, {"Citation": "Bacha U, Barrila J, Velazquez-Campoy A, Leavitt SA, Freire E. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 2004; 43(17):4906\u201312.", "ArticleIdList": ["15109248"]}, {"Citation": "Elfiky AA. SARS-CoV-2 RNA dependent RNA poly-merase (RdRp) targeting: An in silico perspective. J Biomol Struct Dyn 2020;1\u20139.", "ArticleIdList": ["PMC7222627", "32338164"]}, {"Citation": "Balmeh N, Mahmoudi S, Mohammadi N, Karabedian-hajiabadi A. Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors. Inform Med Unlocked 2020;100407.", "ArticleIdList": ["PMC7411426", "32835083"]}, {"Citation": "Xu Z, Peng C, Shi Y, Zhu Z, Mu K, Wang X, et al. Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. BioRxiv. 2020;"}, {"Citation": "Li Y, Zhang J, Wang N, Li H, Shi Y, Guo G, et al. Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening. BioRxiv. 2020;"}, {"Citation": "Khan RJ, Jha RK, Amera GM, Jain M, Singh E, Pathak A, et al. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2\u2032-O-ribose methyl-transferase. J Biomol Struct Dyn 2020;1\u201314.", "ArticleIdList": ["PMC7189412", "32266873"]}, {"Citation": "Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. J Biomol Struct Dyn 2020;2607\u201316.", "ArticleIdList": ["32238094"]}, {"Citation": "Hendaus MA. Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19): A simplified summary. J Biomol Struct Dyn 2020;1\u20136.", "ArticleIdList": ["PMC7256348", "32396771"]}, {"Citation": "Food and Drug Administration .Remdesivir EUA Letter of Authorization - FDA [Internet]. Vol. 364 KB. 2020. p. 6. Available from: https://www.fda.gov/media/137564/download."}, {"Citation": "Kadioglu O, Saeed M, Johannes Greten H, Efferth T. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning. Comput Biol Med 2021;133:104359.", "ArticleIdList": ["PMC8008812", "33845270"]}], "ReferenceList": []}], "History": [{"Year": "2020", "Month": "10", "Day": "7"}, {"Year": "2021", "Month": "1", "Day": "4"}, {"Year": "2021", "Month": "9", "Day": "6", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "7", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "7", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "7", "Day": "1"}], "PublicationStatus": "ppublish", "ArticleIdList": ["34484639", "PMC8377408", "10.18502/ajmb.v13i3.6370", "AJMB-13-107"]}}], "PubmedBookArticle": []}